Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine March 2017, 58 (3) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

AI in medicine: Forsting offers perspective on the challenges, promise, and inevitability of artificial intelligence algorithms as an essential part of future medical imaging practice.

Page 357

Imaging vulnerable plaque: Krishnan and colleagues provide a brief overview of current and promising tracers for molecular imaging of vulnerable coronary plaque and identify hurdles to routine adoption in clinical practice.

Page 359

Radiomics in PET/CT: Hatt and colleagues look at the current paradigm for high-throughput extraction of quantitative metrics from medical images and preview a related article in this issue of JNM.

Page 365

18F-FASu oxidative stress imaging: Yang and colleagues evaluate the suitability of the PET tracer 18F-5-fluoroaminosuberic acid for functional monitoring of system xC− and discuss its potential for diagnosis and treatment monitoring in certain breast cancers.

Page 367

18F-clofarabine dosimetry: Barrio and colleagues report on human whole-body and organ dosimetry of this nucleotide purine analog, a substrate for a key enzyme in the deoxyribonucleoside salvage pathway, and describe its potential as a predictive biomarker for drug response.

Page 374

68Ga-NOTA-AE105 uPAR PET: Skovgaard and colleagues investigate urokinase-type plasminogen activator receptor PET imaging in a first-in-human, phase I trial in breast, prostate, and urinary bladder cancer and detail safety, biodistribution in normal tissues, and uptake in tumor lesions.

Page 379

Understanding texture indices: Orlhac and colleagues analyze changes in values in 6 PET-derived texture indices computed from simulated and real patient data and provide guidance for nuclear medicine physicians in interpreting these indices in clinical practice.

Page 387

18F-FLT PET repeatability: Lodge and colleagues evaluate the consistency of 18F-FLT PET findings from a multicenter trial involving patients with high-grade glioma and establish ranges beyond which SUV differences are likely the result of biologic effects.

Page 393

Low-dose PET lung screening: Schaefferkoetter and colleagues apply a PET/CT analysis platform in patients with malignant lung nodules to determine the lowest practical limits for accurate image quantification while maximizing sensitivity for small, isolated lung lesions.

Page 399

PET/CT texture feature repeatability: Desseroit and colleagues assess the test–retest reliability of shape and heterogeneity features in both the PET and the low-dose CT components of PET/CT and investigate the impact of image quantization.

Page 406

18F-fluciclovine PET in radiotherapy: Jani and colleagues explore the role of this synthetic amino acid PET radiotracer in modifying defined clinical and treatment-planning target volumes in postprostatectomy patients undergoing salvage radiotherapy and also estimate doses to organs at risk.

Page 412

11C-MET or 18F-FDG PET/CT for lymphoma: Kaste and colleagues look at tumor uptake of these 2 tracers in children and young adults with Hodgkin or non-Hodgkin lymphoma and compare relative biodistributions.

Page 419

18F-PSMA-1007 preclinical evaluation: Cardinale and colleagues report on production of and in vitro and small-animal prostate-specific membrane antigen targeting with this radiofluorinated molecule resembling the structure of therapeutic PSMA-617.

Page 425

Labeling and quality control of PSMAHBED: Eppard and colleagues describe optimized labeling of this prostate-specific membrane antigen inhibitor using cation-exchange postprocessing of 68Ga as well as a thin-layer chromatography–based quality control system.

Page 432

PSMA PET as 223Ra gatekeeper: Ahmadzadehfar and colleagues retrospectively evaluate the utility of 68Ga-PSMA-11 PET for planning 223RaCl2 therapy in patients with metastatic prostate cancer, review therapeutic response, and correlate PSA changes with follow-up PSMA PET imaging.

Page 438

177Lu-PSMA I&T dosimetry: Okamoto and colleagues estimate absorbed doses for normal organs and tumor lesions using this theranostic prostate-specific membrane antigen ligand in patients undergoing up to 4 cycles of therapy.

Page 445

64Cu-DOTATATE vs. 68Ga-DOTATOC for NETs: Johnbeck and colleagues report on same-patient comparisons of the diagnostic performance of these 2 PET tracers in neuroendocrine tumors.

Page 451

P2X7R as a neuroinflammation biomarker: Territo and colleagues report on initial physical and biologic characterization of this novel purinergic receptor subtype, which has high receptor affinity, high blood–brain barrier penetration, and the ability to be radiolabeled with 11C.

Page 458

Quantifying 18F-SCH442416 analogs: Khanapur and colleagues determine an appropriate compartmental model for tracer kinetics, evaluate a reference tissue approach, and select the most suitable cerebral adenosine A2A receptor–specific PET ligands in preclinical studies.

Page 466

11C-nicotine radiation dosimetry: Garg and colleagues assess the in vivo distribution of 11C-nicotine and absorbed radiation dose from whole-body 11C-nicotine PET imaging in 11 healthy individuals.

Page 473

Parametric methods for 11C-phenytoin PET: Mansor and colleagues detail the performance of various methods for generating quantitative parametric images of dynamic 11C-phenytoin PET studies in data from healthy individuals.

Page 479

18F-T807 pharmacokinetics in humans: Wooten and colleagues use dynamic PET imaging and metabolite-corrected arterial input functions to characterize the pharmacokinetics of this tracer developed for imaging tau protein aggregates.

Page 484

18F-FDG and MMF: Van Der Gucht et al. use 18F-FDG PET imaging to detail brain metabolic abnormalities in patients with macrophagic myofascitis and explore correlations with cognitive dysfunction.

Page 492

CXCR4 imaging in atherosclerosis: Hyafil and colleagues analyze the ability of 68Ga-pentixafor to detect CXCR4 expression on the surface of inflammatory cells in atherosclerotic plaques in a rabbit model.

Page 499

PET and autoimmune disease: Ahn and colleagues evaluate the clinical significance of 18F-FDG uptake by the spleen in patients with febrile autoimmune disease.

Page 507

99Mo without a nuclear reactor: Youker and colleagues report results for production of 99Mo from accelerator-driven subcritical fission of an aqueous solution containing low-enriched uranium.

Page 514

  • © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (3)
Journal of Nuclear Medicine
Vol. 58, Issue 3
March 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Mar 2017, 58 (3) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Mar 2017, 58 (3) 8A;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Optimization of Labeling PSMAHBED with Ethanol-Postprocessed 68Ga and Its Quality Control Systems
  • Repeatability of 18F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma
  • Preclinical Evaluation and Quantification of 18F-Fluoroethyl and 18F-Fluoropropyl Analogs of SCH442416 as Radioligands for PET Imaging of the Adenosine A2A Receptor in Rat Brain
  • Molecular Imaging of Vulnerable Coronary Plaque: A Pathophysiologic Perspective
  • Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
  • Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer 68Ga-Pentixafor for PET
  • Characterization of 11C-GSK1482160 for Targeting the P2X7 Receptor as a Biomarker for Neuroinflammation
  • 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept
  • Radiomics in PET/CT: More Than Meets the Eye?
  • Quantitative Accuracy and Lesion Detectability of Low-Dose 18F-FDG PET for Lung Cancer Screening
  • Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway
  • Impact of 18F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial
  • Safety, Dosimetry, and Tumor Detection Ability of 68Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging
  • Biodistribution and Radiation Dosimetry of 11C-Nicotine from Whole-Body PET Imaging in Humans
  • Brain 18F-FDG PET Metabolic Abnormalities in Patients with Long-Lasting Macrophagic Myofascitis
  • 18F-5-Fluoroaminosuberic Acid as a Potential Tracer to Gauge Oxidative Stress in Breast Cancer Models
  • Comparison of 11C-Methionine and 18F-FDG PET/CT for Staging and Follow-up of Pediatric Lymphoma
  • Understanding Changes in Tumor Texture Indices in PET: A Comparison Between Visual Assessment and Index Values in Simulated and Patient Data
  • Parametric Methods for Dynamic 11C-Phenytoin PET Studies
  • Reliability of PET/CT Shape and Heterogeneity Features in Functional and Morphologic Components of Non–Small Cell Lung Cancer Tumors: A Repeatability Analysis in a Prospective Multicenter Cohort
  • Evaluation of Spleen Glucose Metabolism Using 18F-FDG PET/CT in Patients with Febrile Autoimmune Disease
  • Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging
  • Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors
  • Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects
  • Machine Learning Will Change Medicine
  • Fission-Produced 99Mo Without a Nuclear Reactor
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire